BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32512655)

  • 1. Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma.
    Vockova P; Svaton M; Karolova J; Pokorna E; Vokurka M; Klener P
    Folia Biol (Praha); 2020; 66(1):17-23. PubMed ID: 32512655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab.
    Lidický O; Klener P; Machová D; Vočková P; Pokorná E; Helman K; Mavis C; Janoušková O; Etrych T
    J Control Release; 2020 Dec; 328():160-170. PubMed ID: 32860930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
    Vidal-Crespo A; Matas-Céspedes A; Rodriguez V; Rossi C; Valero JG; Serrat N; Sanjuan-Pla A; Menéndez P; Roué G; López-Guillermo A; Giné E; Campo E; Colomer D; Bezombes C; van Bueren JL; Chiu C; Doshi P; Pérez-Galán P
    Haematologica; 2020 Apr; 105(4):1032-1041. PubMed ID: 31296574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
    Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
    Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 9. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
    Bride KL; Vincent TL; Im SY; Aplenc R; Barrett DM; Carroll WL; Carson R; Dai Y; Devidas M; Dunsmore KP; Fuller T; Glisovic-Aplenc T; Horton TM; Hunger SP; Loh ML; Maude SL; Raetz EA; Winter SS; Grupp SA; Hermiston ML; Wood BL; Teachey DT
    Blood; 2018 Mar; 131(9):995-999. PubMed ID: 29305553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD38-Targeted Theranostics of Lymphoma with
    Kang L; Li C; Rosenkrans ZT; Huo N; Chen Z; Ehlerding EB; Huo Y; Ferreira CA; Barnhart TE; Engle JW; Wang R; Jiang D; Xu X; Cai W
    Adv Sci (Weinh); 2021 May; 8(10):2001879. PubMed ID: 34026426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CD38
    Sarkar S; Chauhan SKS; Daly J; Natoni A; Fairfield H; Henderson R; Nolan E; Swan D; Hu J; Reagan MR; O'Dwyer M
    Cancer Immunol Immunother; 2020 Mar; 69(3):421-434. PubMed ID: 31919623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial.
    Lim SH; Linton KM; Collins GP; Dhondt J; Caddy J; Rossiter L; Vadher K; Fines K; Rogers LE; Fernando D; Stanton L; Davies AJ; Johnson PWM; Griffiths G
    Trials; 2018 Nov; 19(1):619. PubMed ID: 30413184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma.
    Coleman M; Lammers PE; Ciceri F; Jacobs IA
    Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):175-81. PubMed ID: 26906106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
    Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
    Paul B; Atrash S; Bhutani M; Voorhees P; Hamadeh I; Usmani SZ
    Expert Rev Hematol; 2020 Aug; 13(8):795-802. PubMed ID: 32659139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.